PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20109072-10	2010	(3) The expression of bone morphogenetic protein-2 (BMP-2) mRNA and receptor activator of NF-kB ligand (RANKL) mRNA were upregulated in mevastatin-treated bone.	mevastatin	136-146	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	68-102	
20109072-10	2010	(3) The expression of bone morphogenetic protein-2 (BMP-2) mRNA and receptor activator of NF-kB ligand (RANKL) mRNA were upregulated in mevastatin-treated bone.	mevastatin	136-146	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	104-109	
20109072-11	2010	These results suggest that the topical infusion of mevastatin increases bone mass of isografted bone by increasing bone turnover and, at least in part, by promoting the expression of BMP-2 and RANKL mRNA.	mevastatin	51-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	193-198	
15588717-5	2005	Mevastatin, 0.1-0.6 microM, inhibited the formation of pOCs induced by receptor activator of nuclear factor-kappaB ligand (RANKL) or tumor necrosis factor (TNF-alpha) in both cell cultures.	mevastatin	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	71-121	
16278780-7	2005	On the other hand, 10(-6) M mevastatin and simvastatin inhibited the level of RANKL mRNA in these cultures.	mevastatin	28-38	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	78-83	
15588717-5	2005	Mevastatin, 0.1-0.6 microM, inhibited the formation of pOCs induced by receptor activator of nuclear factor-kappaB ligand (RANKL) or tumor necrosis factor (TNF-alpha) in both cell cultures.	mevastatin	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	123-128